title: Insulin resistance and body composition in Turner syndrome: Effect of sequential change in the route of estrogen administration.
abstract: The aim of the present study was to examine the impact of sequential change in the route of estrogen administration on body composition and insulin resistance in patients with Turner syndrome (TS) using cyclical hormone replacement therapy (HRT) with conjugated equine estrogens (CEE) plus medroxyprogesterone acetate (MPA). We carried out a self-controlled study of nine non-obese patients with TS, with an average age of 23 +/- 4.9 years. Body mass index (BMI), waist-to-hip ratio (WHR), fasting glycemia, insulin tolerance (glucose disappearance constant during an insulin tolerance test, kITT) and body composition (dual-energy X-ray absorptiometry) were studied after 1 year's use of CEE plus MPA and repeated after 1 year's use of 17beta-estradiol gel with the same schedule of MPA administration. We did not observe any difference between the oral and percutaneous HRT with regard to BMI, WHR and insulin tolerance (kITT: 4.9 +/- 1.5 vs. 5.3 +/- 1.5%/min, p = 0.8). During administration of the 17beta-estradiol gel a tendency to increased total lean mass (p = 0.054) was observed. We conclude that sequential change in the route of estrogen administration in TS patients using cyclical HRT with CEE and MPA does not affect insulin resistance, although use of percutaneous 17beta-estradiol gel seems to exert favorable changes in body composition.
authors.affiliation: Department of Endocrinology, Faculty of Medicine, Clementino Fraga Filho Hospital, Federal University of Rio de Janeiro, Brazil. solangefig@openlink.com.br
authors.forename: Solange Travassos de Figueiredo
authors.initials: ST
authors.lastname: Alves
authors.forename: Carla Tavares
authors.initials: CT
authors.lastname: Gallichio
authors.forename: Marília Martins
authors.initials: MM
authors.lastname: Guimarães
mesh_terms: D000293:Adolescent; D000328:Adult; D001786:Blood Glucose / Q000187:drug effects; D001823:Body Composition / Q000187:drug effects*; D050218:Body Fat Distribution; D015992:Body Mass Index; D004333:Drug Administration Routes; D015914:Estrogen Replacement Therapy; D004966:Estrogens, Conjugated (USP) / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007333:Insulin Resistance; D014424:Turner Syndrome / Q000188:drug therapy*
chemical_list: D001786:Blood Glucose; D004966:Estrogens, Conjugated (USP)